Phenomix Corp., a San Diego-based drug developer, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol PHMX, with Morgan Stanley and Credit Suisse serving as co-lead underwriters. Phenomix has now raised around $125 million in total VC funding since its 2001 founding, including a $55 million Series C round last year.
Â
Backers include JPMorgan Partners (18% pre-IPO stake), Nomura Phase4 Ventures (15.8%), Delphi Ventures (11.1%), Alta Partners (9.8%), Sofinnova Ventures (9.8%), Novartis BioVenture Fund  (9.1%), Baker Brothers (7.6%), Bay City Capital (6.5%), CMEA Ventures (5.8%) and GBS Venture Partners.
Â
The company’s most advanced programs include a Phase II inhibitor of the protease DPP4 for treatment of Type 2 diabetes, and a preclinical program inhibiting NS3 protease for treatment of hepatitis C.www.phenomixcorp.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.